US 12,458,657 B2
Neurogenesis
Justin R. Fallon, Providence, RI (US); Ashley E. Webb, Providence, RI (US); Beth McKechnie, Attleboro, MA (US); Tali Sorets, Newton, MA (US); Lauren Fish, East Greenwich, RI (US); Diego Jaime, Providence, RI (US); John Page, Storrs, CT (US); and Laura A. Madigan, Pawtucket, RI (US)
Assigned to BROWN UNIVERSITY, Providence, RI (US)
Appl. No. 17/604,279
Filed by Brown University, Providence, RI (US)
PCT Filed Apr. 17, 2020, PCT No. PCT/US2020/028816
§ 371(c)(1), (2) Date Oct. 15, 2021,
PCT Pub. No. WO2020/214987, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/835,945, filed on Apr. 18, 2019.
Prior Publication US 2022/0193114 A1, Jun. 23, 2022
Int. Cl. A61K 48/00 (2006.01); A01K 67/0276 (2024.01); A61K 31/7105 (2006.01); C07K 16/18 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/7105 (2013.01) [A01K 67/0276 (2013.01); C07K 16/18 (2013.01); C12N 15/111 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method of treating a subject suffering from one or more features of neurodegeneration or impaired cognition that would benefit from increased neurogenesis by delivering an oligonucleotide to the brain of the subject:
wherein the oligonucleotide targets a MuSK transcript that is expressed in the brain of the subject and alters splicing so that one or more exons encoding the MuSK Ig3 domain are skipped;
wherein the level or activity of a MuSK polypeptide lacking a functional Ig3 domain (MuSKΔlg3) relative to other MuSK polypeptides that include a functional lg3 domain is increased; and
wherein the level or activity of protein-protein complexes that include a MuSK polypeptide with a functional lg3 domain complexed with bone morphogenic protein (BMP) relative to the MuSK polypeptide lacking a functional lg3 domain is reduced.